Zhejiang Shengda Bio-Pharm Co Ltd
SSE:603079
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.5
21.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Zhejiang Shengda Bio-Pharm Co Ltd's stock price target?
Not Available
Zhejiang Shengda Bio-Pharm Co Ltd doesn't have any price targets made by Wall Street professionals.
What is Zhejiang Shengda Bio-Pharm Co Ltd's Revenue forecast?
Projected CAGR
-6%
For the last 9 years the compound annual growth rate for Zhejiang Shengda Bio-Pharm Co Ltd's revenue is 5%. The projected CAGR for the next 7 years is -6%.
What is Zhejiang Shengda Bio-Pharm Co Ltd's Net Income forecast?
Projected CAGR
14%
For the last 9 years the compound annual growth rate for Zhejiang Shengda Bio-Pharm Co Ltd's net income is -11%. The projected CAGR for the next 7 years is 14%.
